参芪扶正注射液联合化疗治疗癌症的系统评价再评价
该再评价纳入32篇参芪扶正注射液联合化疗治疗癌症的系统评价/Meta分析,采用PRISMA 2020、AMSTAR 2、ROBIS和GRADE评估质量。结果显示联合治疗可能提高临床疗效(肝癌除外)、生活质量和免疫功能(CD8+除外),并减少白细胞减少等不良事件,但多数证据质量低。
要点
- 参芪扶正注射液联合化疗可能改善多种癌症的临床疗效、生活质量和免疫功能。
- 联合治疗可能减少白细胞减少、血小板减少等化疗相关不良事件。
- 纳入系统评价的方法学质量均极低,证据质量以低或极低为主。
核心结论
- 参芪扶正注射液联合化疗可能提高各类癌症的临床疗效(肝癌除外)、生活质量和免疫功能(CD8+除外),并减少白细胞减少等不良事件,但多数临床证据质量低。
研究设计与样本
- 研究为系统评价再评价,全面检索PubMed、Web of Science、Embase、Cochrane Library、CNKI、VIP、WanFang和CBM从建库至2023年9月30日。
- 纳入参芪扶正注射液联合化疗治疗癌症的随机对照试验的系统评价/Meta分析,共纳入32篇SRs/MAs。
- 由四名评价员筛选文献并提取信息,五名评价员评估报告质量、方法学质量、偏倚风险和证据质量。
- 采用校正覆盖面积(CCA)评估SRs/MAs纳入RCT的重叠程度,并对结果进行描述性分析。
主要发现
- 采用PRISMA 2020评估报告质量:1篇SR/MA报告相对完整,20篇有一些缺陷,11篇有严重缺陷。
- 采用AMSTAR 2评估方法学质量:所有SRs/MAs的方法学质量均极低。
- 采用ROBIS评估偏倚风险:19篇SRs/MAs偏倚风险低,13篇偏倚风险不明确。
- 采用GRADE评估证据质量:50个条目为中等质量,46个为低质量,27个为极低质量,85个不明确。
- 参芪扶正注射液联合化疗在提高临床疗效(肝癌除外)、生活质量、免疫功能(CD8+除外)以及减少白细胞减少、血小板减少、血红蛋白减少、恶心呕吐、肝损伤、肾损伤、神经毒性、脱发和腹泻等方面发挥作用。
关键数值与推荐
- 报告质量:1篇相对完整,20篇有一些缺陷,11篇严重缺陷(PRISMA 2020)。
- 方法学质量:所有SRs/MAs均极低(AMSTAR 2)。
- 偏倚风险:19篇低,13篇不明确(ROBIS)。
- 证据质量:50个条目中等,46个低,27个极低,85个不明确(GRADE)。
临床怎么用
- 参芪扶正注射液联合化疗可能作为改善临床疗效、生活质量和免疫功能的辅助治疗选择,但需考虑证据质量低的限制。
- 临床决策时应结合患者具体情况,并关注联合治疗可能减少化疗相关不良事件(如白细胞减少、血小板减少等)的潜在获益。
局限性
- 纳入的系统评价/Meta分析方法学质量均极低,报告质量存在缺陷,证据质量以低或极低为主。
- 多数临床证据质量低,未来需要更高质量的临床试验来提高上述结论的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In China, Shenqi Fuzheng injection (SFI) has been used as an adjuvant therapy to treat all kinds of cancer for many years. A large number of systematic reviews or meta-analyses (SRs/MAs) were published to assess its efficacy and safety in the past few years. However, the quality of SRs/MAs was unclear and did not generate high-quality clinical evidence. OBJECTIVE: We conducted an overview to integrate relevant SRs/MAs published in the past with the aim of providing new clinical evidence for SFI in combination with chemotherapy in the treatment of cancer. OBJECTIVE: We conducted an overview to integrate relevant SRs/MAs published in the past with the aim of providing new clinical evidence for SFI in combination with chemotherapy in the treatment of cancer. METHODS: A comprehensive search of PubMed, Web of Science, Embase, the Cochrane Library, CNKI, VIP, WanFang, and CBM was performed from the database inception to September 30, 2023. SRs/MAs of randomized controlled trials (RCTs) on SFI combined with chemotherapy for cancer were included. Four reviewers screened the literature and extracted relevant information. Five reviewers assessed the quality of reporting, methodological quality, risk of bias, and quality of evidence for SRs/MAs. We used corrected covered area (CCA) to assess the degree of overlap among the RCTs included in SRs/MAs. We performed a descriptive analysis for the results of the included SRs/MAs. RESULTS: A total of 32 SRs/MAs of SFI combined with chemotherapy for cancer were included. We assessed the reporting quality of SRs/MAs using the PRISMA 2020 statement. 1 SR/MA had relatively complete reports, 20 SRs/MAs had some deficiencies in reporting, and 11 SRs/MAs had serious deficiencies in reporting. We assessed the methodological quality of SRs/MAs using the AMSTAR 2 tool. The methodological quality of all SRs/MAs was very low. We assessed the risk of bias for SRs/MAs using the ROBIS tool. The risk of bias was low for 19 SRs/MAs and unclear for 13 SRs/MAs. We assessed the quality of evidence for SRs/MAs using the GRADE evidence quality evaluation system. 50 items were moderate quality, 46 items were low quality, 27 items were very low quality, and 85 items were unclear. SFI combined with chemotherapy played a role in increasing efficacy and decreasing toxicities in all kinds of cancer, including clinical efficacy (except liver cancer), quality of life, immune function (except CD8+), leukopenia, thrombocytopenia, hemoglobinopenia, nausea and vomiting, liver damage, kidney damage, neurotoxicity, alopecia, and diarrhea. CONCLUSION: The overview showed that SFI combined with chemotherapy may improve clinical efficacy (except for liver cancer), quality of life, and immune (except for CD8+) function in all types of cancer, as well as adverse events (AEs) such as leukopenia, thrombocytopenia, etc. Since most of the clinical evidence was low, higher quality clinical trials will be expected to improve the reliability of the above conclusions in the future.
引用
- Chen G, Lu J, Li B, et al. Efficacy and safety of Shenqi Fuzheng injection combined with chemotherapy for cancer: An overview of systematic reviews. Phytomedicine. 2023. PMID: 38295658. doi:10.1016/j.phymed.2023.155293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。